These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 4935417)

  • 21. Molecular basis of Escherichia coli colonization of the upper urinary tract in BALB/c mice. Gal-Gal pili immunization prevents Escherichia coli pyelonephritis in the BALB/c mouse model of human pyelonephritis.
    O'Hanley P; Lark D; Falkow S; Schoolnik G
    J Clin Invest; 1985 Feb; 75(2):347-60. PubMed ID: 2857730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of pyelonephritis by immunization with P-fimbriae.
    Roberts JA; Hardaway K; Kaack B; Fussell EN; Baskin G
    J Urol; 1984 Mar; 131(3):602-7. PubMed ID: 6199527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody production in urinary bladder infection.
    Uehling DT; Barnhart DD; Seastone CV
    Invest Urol; 1968 Sep; 6(2):211-22. PubMed ID: 4877423
    [No Abstract]   [Full Text] [Related]  

  • 24. P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis.
    Roberts JA; Kaack MB; Baskin G; Korhonen TK; Svenson SB; Winberg J
    Pediatr Nephrol; 1989 Oct; 3(4):391-6. PubMed ID: 2577147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of the bladder defense mechanism by immunization.
    Uehling DT; Wolf L
    Invest Urol; 1969 Mar; 6(5):520-6. PubMed ID: 4887493
    [No Abstract]   [Full Text] [Related]  

  • 26. Immunoprotection of guinea pigs against experimental acute pyelonephritis after the administration of Escherichia coli purified fimbriae.
    Dima VF; Petrovici A; Dima SV; Petrovici M; Burghelea B
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):215-25. PubMed ID: 2577515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Infectivity and spreading pathway of E. coli in the kidneys in experimental rat pyelonephritis].
    Tuan H; Briedigkeit H; Ditscherlein G; Dutz W; Hagemann I; Thilo W
    Acta Biol Med Ger; 1970; 25(4):679-91. PubMed ID: 4932462
    [No Abstract]   [Full Text] [Related]  

  • 28. Antibody responses and protection from pyelonephritis following vaccination with purified Escherichia coli PapDG protein.
    Roberts JA; Kaack MB; Baskin G; Chapman MR; Hunstad DA; Pinkner JS; Hultgren SJ
    J Urol; 2004 Apr; 171(4):1682-5. PubMed ID: 15017266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaginal immunization against urinary tract infection.
    Uehling DT; Jensen J; Balish E
    J Urol; 1982 Dec; 128(6):1382-4. PubMed ID: 6759690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new candidate vaccine for Escherichia coli pyelonephritis.
    Stapleton A
    J Urol; 2004 Apr; 171(4):1686-7. PubMed ID: 15017267
    [No Abstract]   [Full Text] [Related]  

  • 31. [An experimental model of ascending pyelonephritis in rats].
    Chilimoniuk M; Jodczyk JK; Dzierzanowska D; Musierowicz A; Korfel Z
    Med Dosw Mikrobiol; 1977; 29(1):67-71. PubMed ID: 323605
    [No Abstract]   [Full Text] [Related]  

  • 32. Prevention of pyelonephritis due to Escherichia coli in rats with gentamicin stored in kidney tissue.
    Glauser MP; Lyons JM; Braude AI
    J Infect Dis; 1979 Feb; 139(2):172-7. PubMed ID: 374643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Divalent flagellin immunotherapy provides homologous and heterologous protection in experimental urinary tract infections in mice.
    Sabharwal N; Chhibber S; Harjai K
    Int J Med Microbiol; 2016 Jan; 306(1):29-37. PubMed ID: 26655680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization against retrograde pyelonephritis. I. Production of an experimental model of severe ascending Escherichia coli pyelonephritis without bacteremia in rats.
    Brooks SJ; Lyons JM; Braude AI
    Am J Pathol; 1974 Feb; 74(2):345-58. PubMed ID: 4590645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of indomethacin on the incidence of experimental Escherichia coli pyelonephritis.
    Glauser MP; Francioli PB; Bille J; Bonard M; Meylan P
    Infect Immun; 1983 May; 40(2):529-33. PubMed ID: 6341240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary tract infection. Experimental induction in rats.
    Rosini S; Benetti D
    Int Urol Nephrol; 1972; 4(4):333-40. PubMed ID: 4592802
    [No Abstract]   [Full Text] [Related]  

  • 37. Antigen presentation as a factor in the protective immune response to renal infection.
    Miller TE; Burnham S
    Clin Exp Immunol; 1975 Nov; 22(2):265-78. PubMed ID: 765022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Experimental pyelonephritis in the cat. 1. Gross and histological changes.
    Kelly DF; Lucke VM; McCullagh KG
    J Comp Pathol; 1979 Jan; 89(1):125-39. PubMed ID: 370162
    [No Abstract]   [Full Text] [Related]  

  • 39. Experimental pyelonephritis. XV. Increased susceptibility to E. coli infection in old rats.
    Freeman LR
    Yale J Biol Med; 1969 Aug; 42(1):30-8. PubMed ID: 4899641
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of active and passive immunization on the development of experimental Pseudomonas aeruginosa pyelonephritis in mice.
    Petit JC; Sicard D; Bayo S; Daguet GL
    Can J Microbiol; 1981 Jan; 27(1):93-7. PubMed ID: 6783287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.